Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.2857.

HUMA has been the subject of several recent analyst reports. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Humacyte in a research report on Monday, December 1st. Benchmark lowered their price objective on shares of Humacyte from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. UBS Group reissued a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday, December 22nd.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $1.07 on Monday. The stock’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $1.75. The stock has a market capitalization of $200.38 million, a price-to-earnings ratio of -4.65 and a beta of 1.90. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. Humacyte has a 52-week low of $1.04 and a 52-week high of $5.66.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. The company had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.92 million. As a group, sell-side analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. acquired a new stake in shares of Humacyte during the first quarter worth approximately $5,648,000. Marshall Wace LLP boosted its stake in shares of Humacyte by 5,308.2% during the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after buying an additional 2,590,394 shares during the period. CenterBook Partners LP grew its holdings in shares of Humacyte by 141.1% during the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after acquiring an additional 2,007,743 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Humacyte by 38.7% during the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock valued at $6,735,000 after acquiring an additional 1,101,198 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after acquiring an additional 738,142 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.